Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Illumina (NASDAQ:ILMN) and its peers.

Infectious keratitis remains a leading cause of corneal blindness and visual impairment worldwide, with bacterial, fungal, amoebic and viral pathogens presenting major diagnostic and therapeutic ...

An international research team has succeeded in developing a new version of RNA building blocks with higher chemical reactivity and photosensitivity. This can significantly reduce the production time ...

Non-invasive prenatal testing (NIPT) is a simple blood test during pregnancy that helps detect rare genetic conditions early, ...

Methods developed and validated to establish the "World Bank of NK Cells" from healthy donors and cancer patients -- Single apheresis yields up to 5 billion (5×109) highly pure activated memory ...

When analyzing the drug delivery product pipeline, three key technologies stand out. Check out the latest market research.